{"id":"tp-53348","type":"article-newspaper","title":"FDA Requires GLP-1 Drug Labels to Disclose Potential NAION Risk","author":"Riza Dagoc","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/regulation/53348","datePublished":"2026-11-10T21:58:59.000Z","dateModified":"2026-11-10T21:58:59.000Z","language":"en","abstract":"The Nov. 9, 2026, requirement covers medicines used for diabetes, weight loss and other approved purposes.","section":"Regulation","references":[]}